摘要
背景:到2019年底,新型冠状病毒病(COVID-19)的突然爆发已成为全球性威胁。之所以称为 COVID-19,是因为它是由 2019 年的新型冠状病毒(SARS-COV-2)引起的。 全世界共报告了 190 万例死亡和 8790 万例病例,迄今已治愈 4900 万例。科学家们正在努力寻找 COVID-19 的化疗药物和疫苗。在几种危险压力的组合中观察到 SARS-CoV-2 的突变,使它们更具抵抗力和益处。因此,为了分解病毒系统,需要检查疾病目标。 目的:在现今的综述中,对刺突蛋白的综合研究解释了新型冠状病毒的主要用途以及如何防止疾病病毒从感染者交叉传播到健康人。 方法: Covid-19 已被世界卫生组织 (WHO) 宣布为大流行病,因为它会在全球范围内导致死亡和严重疾病。 SARS-CoV-2 具有高度传染性;然而,新型冠状病毒的中间宿主尚不清楚。为了探索疾病的机制,病毒靶点之一,例如与人类细胞结合并通过改变其遗传结构引起疾病的刺突蛋白,这被认为是潜在的抑制剂。 结果:已表明SARS-CoV-2刺突的受体结合域(RBD)蛋白与血管紧张素转换酶2(ACE2)宿主受体的相互作用以及冠状病毒刺突蛋白的进一步复制导致其入侵宿主细胞。人类淋巴细胞抗原 6 复合物 Locus E (LY6E) 通过干扰人类基因、诱导刺突蛋白介导的膜融合来抑制 CoV 进入宿主细胞。一些天然配方也被证明可以防止刺突蛋白与宿主细胞结合。 结论:随着可抑制刺突蛋白-ACE2介导的膜融合的LY6E基因激活剂的开发,SARS-CoV-2治疗的新机会可能出现。现有的抗病毒融合抑制剂和针对刺突抗性的天然化合物可以作为进一步 SARS-CoV-2 药物制剂的模板。
关键词: COVID-19,刺突蛋白潜在冠状病毒靶点,基因改造,天然药物,交叉感染预防,ACE2。
Current Drug Targets
Title:Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents
Volume: 22 Issue: 17
关键词: COVID-19,刺突蛋白潜在冠状病毒靶点,基因改造,天然药物,交叉感染预防,ACE2。
摘要:
Background: By the end of 2019, the sudden outbreak of the novel coronavirus disease (COVID-19) has become a global threat. It is called COVID-19 because it was caused by the novel coronavirus (SARS-COV-2) in 2019. A total of 1.9 M deaths and 87.9 M cases have been reported all over the world, where 49M cases have recovered so far. Scientists are working hard to find chemotherapeutics and vaccines for COVID-19. Mutations in SARS-CoV-2 have been observed in a combination of several hazardous stresses, making them more resistant and beneficial. So to break down the viral system, the disease targets are examined.
Objective: In today's review, a comprehensive study of spike protein explains the main purpose of the novel coronavirus and how to prevent the spread of the disease virus cross-transmission from infected to a healthy person.
Methods: Covid-19 has already been declared a pandemic by the World Health Organization (WHO) due to its result in causing death and severe illness globally. SARS-CoV-2 is highly contagious; however, the intermediate host of the novel coronavirus is not clear. To explore the mechanisms of disease, one of the viral targets, such as the spike protein that binds to human cells and causes the disease by altering its genetic structure which is considered along with potential inhibitors.
Results: It has been shown that the interaction of receptor-binding domain (RBD) protein of SARS- CoV-2 spike and the angiotensin-converting enzyme 2 (ACE2) host receptor and further replication of coronavirus spike protein causes its invasion in the host cell. The human Lymphocyte antigen 6 complex, Locus E (LY6E), inhibits the entry of CoV into host cells by interfering with the human gene, inducing spike protein-mediated membrane fusion. Some natural formulations have also been shown to prevent spike protein from binding to the host cell.
Conclusion: With the development of the LY6E gene activator that can inhibit spike protein- ACE2-mediated membrane fusion, new opportunities for SARS-CoV-2 treatment may emerge. Existing antiviral fusion inhibitors and natural compounds targeting spike resistance can serve as a template for further SARS-CoV-2 drug formulation.
Export Options
About this article
Cite this article as:
Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents, Current Drug Targets 2021; 22 (17) . https://dx.doi.org/10.2174/1389450122666210309105820
DOI https://dx.doi.org/10.2174/1389450122666210309105820 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Advances in Design and Development of Inhibitors of Nitric Oxide Synthases
Current Enzyme Inhibition Hedgehog Signaling and Urological Cancers
Current Drug Targets Recent Software Developments and Applications in Functional Imaging
Current Pharmaceutical Biotechnology Potential Clinical Applications of Multi-functional Milk Proteins and Peptides in Cancer Management
Current Medicinal Chemistry Comparing the Molecular Pharmacology of CGRP and Adrenomedullin
Current Protein & Peptide Science The Association of Chemotherapy and Radiotherapy: Breast Cancer
Current Drug Therapy Treatment of Allergic Asthma by Targeting Transcription Factors Using Nucleic-Acid Based Technologies
Current Pharmaceutical Design Evidence-Based Review of Physiologic Effects of Kangaroo Care
Current Women`s Health Reviews L-Arginine Signalling Potential in the Brain: The Peripheral Gets Central
Recent Patents on CNS Drug Discovery (Discontinued) Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology Ethanol Metabolism and Effects: Nitric Oxide and its Interaction
Current Clinical Pharmacology Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor
Current Pharmaceutical Design The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Asthma-COPD Overlap: A more Simplistic Approach
Current Respiratory Medicine Reviews Carbon Monoxide, A Two-Face for the Protection of the Liver
Current Pharmaceutical Biotechnology Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations
Current Pharmaceutical Design The Use of Citrullinated Peptides for the Diagnosis and Prognosis of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Non-Covalent Binding of Disodium Disuccinate Astaxanthin to the Catalytic Site of Phosphodiesterase 5A: A Molecular Modeling Study
Letters in Drug Design & Discovery COPD: Optimal Current Treatment Strategies and Promising New Therapeutic Modalities
Current Respiratory Medicine Reviews